{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:53:09Z","timestamp":1769151189979,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00277-018-3571-7","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T19:44:58Z","timestamp":1546976698000},"page":"1169-1176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1153-2294","authenticated-orcid":false,"given":"Dai","family":"Chihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Oki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Fanale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason R.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sattva","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan H.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan Yoon","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,8]]},"reference":[{"issue":"6","key":"3571_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN (2014) An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123(6):837\u2013842. \n                    https:\/\/doi.org\/10.1182\/blood-2013-09-524108","journal-title":"Blood"},{"issue":"1","key":"3571_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJM199807023390104","volume":"339","author":"TP Miller","year":"1998","unstructured":"Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339(1):21\u201326. \n                    https:\/\/doi.org\/10.1056\/NEJM199807023390104","journal-title":"N Engl J Med"},{"issue":"1","key":"3571_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1200\/JCO.2002.20.1.197","volume":"20","author":"TN Shenkier","year":"2002","unstructured":"Shenkier TN, Voss N, Fairey R, Gascoyne RD, Hoskins P, Klasa R, Klimo P, O'Reilly SE, Sutcliffe S, Connors JM (2002) Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 20(1):197\u2013204. \n                    https:\/\/doi.org\/10.1200\/JCO.2002.20.1.197","journal-title":"J Clin Oncol"},{"issue":"25","key":"3571_CR4","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1200\/JCO.2015.65.4582","volume":"34","author":"DM Stephens","year":"2016","unstructured":"Stephens DM, Li H, LeBlanc ML, Puvvada SD, Persky D, Friedberg JW, Smith SM (2016) Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of southwest oncology group study S8736. J Clin Oncol 34(25):2997\u20133004. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.65.4582","journal-title":"J Clin Oncol"},{"key":"3571_CR5","unstructured":"National Comprehensive Cancer Network. (2018) B-cell lymphomas (version 5.2018). \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf"},{"key":"3571_CR6","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1182\/blood-2017-12-791418","volume":"131","author":"M Yamaguchi","year":"2018","unstructured":"Yamaguchi M, Suzuki R, Oguchi M (2018) Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type. Blood 131:2528\u20132540. \n                    https:\/\/doi.org\/10.1182\/blood-2017-12-791418","journal-title":"Blood"},{"issue":"21","key":"3571_CR7","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes C, DeAngelis LM (2017) Primary CNS lymphoma. J Clin Oncol 35(21):2410\u20132418. \n                    https:\/\/doi.org\/10.1200\/JCO.2017.72.7602","journal-title":"J Clin Oncol"},{"issue":"1","key":"3571_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1182\/asheducation-2017.1.298","volume":"2017","author":"K Dunleavy","year":"2017","unstructured":"Dunleavy K (2017) Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies. Hematology Am Soc Hematol Educ Program 2017(1):298\u2013303. \n                    https:\/\/doi.org\/10.1182\/asheducation-2017.1.298","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"3571_CR9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1182\/blood-2013-10-530659","volume":"123","author":"CY Cheah","year":"2014","unstructured":"Cheah CY, Wirth A, Seymour JF (2014) Primary testicular lymphoma. Blood 123(4):486\u2013493. \n                    https:\/\/doi.org\/10.1182\/blood-2013-10-530659","journal-title":"Blood"},{"key":"3571_CR10","doi-asserted-by":"publisher","unstructured":"Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY (2018) Stage I non-Hodgkin lymphoma: difference in survival outcome by primary extranodal site of involvement. Br J Haematol doi:\n                    https:\/\/doi.org\/10.1111\/bjh.15444","DOI":"10.1111\/bjh.15444"},{"issue":"22","key":"3571_CR11","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1182\/blood.V128.22.5330.5330","volume":"128","author":"R Suzuki","year":"2016","unstructured":"Suzuki R, Chihara D, Asano N, Ohmachi K, Kinoshita T, Matsue K, Suzumiya J, Ogura M (2016) Limited-stage mantle cell lymphoma. Blood 128(22):5330\u20135330","journal-title":"Blood"},{"issue":"3","key":"3571_CR12","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/cncr.11096","volume":"97","author":"JE Romaguera","year":"2003","unstructured":"Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, Younes A, McLaughlin P, Goy A, Sarris AH, Dang NH, Samaniego F, Brown HM, Gagneja HK, Cabanillas F (2003) Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 97(3):586\u2013591. \n                    https:\/\/doi.org\/10.1002\/cncr.11096","journal-title":"Cancer"},{"issue":"27","key":"3571_CR13","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1200\/JCO.2009.27.3441","volume":"28","author":"J Phan","year":"2010","unstructured":"Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS (2010) Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 28(27):4170\u20134176. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.27.3441","journal-title":"J Clin Oncol"},{"key":"3571_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","volume":"131","author":"T Lamy","year":"2017","unstructured":"Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuilliez JP, Fest T, Colombat P, Costes V, Szablewski V, Bene MC, Delwail V (2017) R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL). Blood 131:174\u2013181. \n                    https:\/\/doi.org\/10.1182\/blood-2017-07-793984","journal-title":"Blood"},{"issue":"30","key":"3571_CR15","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","volume":"25","author":"GD Shah","year":"2007","unstructured":"Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM, Abrey LE (2007) Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25(30):4730\u20134735. \n                    https:\/\/doi.org\/10.1200\/jco.2007.12.5062","journal-title":"J Clin Oncol"},{"issue":"20","key":"3571_CR16","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO.2010.31.4187","volume":"29","author":"U Vitolo","year":"2011","unstructured":"Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E (2011) First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol 29(20):2766\u20132772. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.31.4187","journal-title":"J Clin Oncol"},{"issue":"7","key":"3571_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11864-015-0351-7","volume":"16","author":"PM Reagan","year":"2015","unstructured":"Reagan PM, Friedberg JW (2015) Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma. Curr Treat Options in Oncol 16(7):32. \n                    https:\/\/doi.org\/10.1007\/s11864-015-0351-7","journal-title":"Curr Treat Options in Oncol"},{"key":"3571_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/hon.2437_11","volume":"35","author":"MP Macmanus","year":"2017","unstructured":"Macmanus MP, Fisher R, Roos D, O'Brien P, Macann A, Tsang R, Davis S, Christie D, McClure B, Joseph D, Seymour JF (2017) CVP or R-CVP given after involved-field radiotherapy improves progression free survival in stage I\u2013II follicular lymphoma: results of an international randomized trial. Hematol Oncol 35:31\u201331. \n                    https:\/\/doi.org\/10.1002\/hon.2437_11","journal-title":"Hematol Oncol"},{"issue":"4","key":"3571_CR19","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1158\/1055-9965.EPI-05-0549","volume":"15","author":"CA Clarke","year":"2006","unstructured":"Clarke CA, Undurraga DM, Harasty PJ, Glaser SL, Morton LM, Holly EA (2006) Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomark Prev 15(4):630\u2013638. \n                    https:\/\/doi.org\/10.1158\/1055-9965.EPI-05-0549","journal-title":"Cancer Epidemiol Biomark Prev"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3571-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3571-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3571-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T19:06:43Z","timestamp":1578424003000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3571-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,8]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["3571"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3571-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,8]]},"assertion":[{"value":"27 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr Fanale reports grants and personal consulting fees through 06\/04\/18 from Seattle Genetics and salary and stocks from 10\/01\/18 following the start of her employment with Seattle Genetics. Grants and personal fees from Takeda through 06\/04\/18, grants and personal fees from Celgene through 06\/04\/18, grants from ADC Therapeutics through 06\/04\/18, grants and personal fees from BMS through 06\/04\/18, grants and personal fees from Merck through 06\/04\/18, grants from Molecular Templates through 06\/04\/18, personal fees from Bayer through 06\/04\/18, personal fees from Spectrum through 06\/04\/18, grants from MedImmune through 06\/04\/18, grants from Gilead through 06\/04\/18, and grants from Genentech through 06\/04\/18.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"SEER data is publically available de-identified database and thus deemed not needing approval from institutional review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}